Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients

Journal of Korean Medical Science

Volumn 28, Issue 8, 2013, Pages 1248-1252

  Yoon, Shinkyo ^a   Ryu, Min Hee ^a   Yoo, Changhoon ^a   Beck, Mo Youl ^a   Ryoo, Baek Yeol ^a   Kang, Yoon Koo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Dose modification; Gastrointestinal stromal tumors (gist); Imatinib; Imatinib plasma monitoring

Indexed keywords

ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

AGED; ARTICLE; BLOOD; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DOSE-MODIFICATION; DRUG MONITORING; EXON; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL STROMAL TUMORS (GIST); GASTROINTESTINAL TUMOR; GENETICS; HUMAN; IMATINIB PLASMA MONITORING; LIVER TUMOR; MALE; METASTASIS; MUTATION; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY;

DOSE-MODIFICATION; GASTROINTESTINAL STROMAL TUMORS (GIST); IMATINIB; IMATINIB PLASMA MONITORING;

AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; DRUG MONITORING; EXONS; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LIVER NEOPLASMS; MALE; MUTATION; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84884377825     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2013.28.8.1248     Document Type: Article

References (13)

1. Demetri GD, von Mehren M, Blanke CD, Van Den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.
2. Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, et al. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor. Oncology 2009; 76: 326-32.
3. Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, Joensuu H, von Mehren M. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009; 27: 3141-7.
4. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22: 935-42.
5. Yoo C, Ryu MH, Kang BW, Yoon SK, Ryoo BY, Chang HM, Lee JL, Beck MY, Kim TW, Kang YK. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 2010; 28: 1554-9.
6. Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec-Rychter M, Csajka C, Biollaz J, Buclin T. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 2008; 98: 1633-40.
7. George S, Trent JC. The role of imatinib plasma level testing in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 2011; 67: S45-50.
8. Ryu MH, Lee JL, Chang HM, Kim TW, Kang HJ, Sohn HJ, Lee JS, Kang YK. Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate. Jpn J Clin Oncol 2006; 36: 17-24.
9. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-103.
10. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010; 28: 1247-53.
11. Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults: analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 1993; 217: 72-7.
12. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44: 879-94.
13. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y; IRIS (International Randomized Interferon vs STI571) Study Group. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS Study. Blood 2008; 111: 4022-8.